Status:
COMPLETED
Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists
Lead Sponsor:
Yale University
Collaborating Sponsors:
Vifor Pharma
Relypsa, Inc.
Conditions:
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible p...
Detailed Description
Despite the robust literature demonstrating improved outcomes with the use of mineralocorticoid antagonists (MRAs) in patients with heart failure with reduced ejection fraction (HFrEF), MRAs continue ...
Eligibility Criteria
Inclusion
- Adults equal to or greater than 18 years of age
- Outpatients of providers randomized into the study within Internal Medicine and Cardiology outpatient clinics
- Diagnosis of heart failure with reduced ejection fraction (LVEF less than or equal to 40% on the most recent TTE)
- Registration in the Yale Heart Failure Registry (NCT04237701)
- Not currently prescribed an MRA
Exclusion
- Absolute contraindication to MRAs
Key Trial Info
Start Date :
November 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2024
Estimated Enrollment :
1210 Patients enrolled
Trial Details
Trial ID
NCT04903717
Start Date
November 3 2021
End Date
February 6 2024
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology/Internal Medicine Outpatient Clinics of Yale New Health System
New Haven, Connecticut, United States, 06510